Respiratory Syncytial Virus Entry Inhibitors Targeting the F Protein
AbstractHuman respiratory syncytial virus (RSV) is the main viral cause of respiratory tract infection in infants as well as some elderly and high-risk adults with chronic pulmonary disease and the severely immunocompromised. So far, no specific anti-RSV therapeutics or effective anti-RSV vaccines have been reported. Only one humanized monoclonal antibody, Palivizumab, has been approved for use in high-risk infants to prevent RSV infection. Ribavirin is the only drug licensed for therapy of RSV infection, but its clinical use is limited by its nonspecific anti-RSV activity, toxic effect, and relatively high cost. Therefore, development of novel effective anti-RSV therapeutics is urgently needed. The RSV envelope glycoprotein F plays an important role in RSV fusion with, and entry into, the host cell and, consequently, serves as an attractive target for developing RSV entry inhibitors. This article reviews advances made in studies of the structure and function of the F protein and the development of RSV entry inhibitors targeting it. View Full-Text
Share & Cite This Article
Sun, Z.; Pan, Y.; Jiang, S.; Lu, L. Respiratory Syncytial Virus Entry Inhibitors Targeting the F Protein. Viruses 2013, 5, 211-225.
Sun Z, Pan Y, Jiang S, Lu L. Respiratory Syncytial Virus Entry Inhibitors Targeting the F Protein. Viruses. 2013; 5(1):211-225.Chicago/Turabian Style
Sun, Zhiwu; Pan, Yanbin; Jiang, Shibo; Lu, Lu. 2013. "Respiratory Syncytial Virus Entry Inhibitors Targeting the F Protein." Viruses 5, no. 1: 211-225.